Total
0
Shares
Creso Pharma (ASX:CPH) - Adam Blumenthal
Adam Blumenthal
Source: EverBlu Capital
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (CPH) has received firm commitments to undertake an $18 million placement
  • All up, roughly 94.7 million new fully-paid ordinary shares will be issued to institutional, professional and sophisticated investors at 19 cents
  • This price represents a 17.4 per cent discount to the last trading price of 23 cents on March 23
  • Subject to shareholder approval, Creso will provide one option to shareholders for every four shares issued exercisable at 38 cents with expiry 12 months from issue
  • Creso will use the money to undertake clinical trials, increase cannabis product marketing in Canada and fund the acquisition of Halucenex Life Sciences
  • Shares in Creso are down 6.52 per cent on the market and are trading at 21.5 cents

Creso Pharma (CPH) has received firm commitments to undertake an $18 million placement.

The company entered a trading halt on March 24 but did not disclose how much it intended to raise or what it would use the funds for.

All up, roughly 94.7 million new fully-paid ordinary shares will be issued to institutional, professional and sophisticated investors at 19 cents.

This price represents a 17.4 per cent discount to the last trading price of 23 cents on March 23 and an 8.8 per cent discount to the 15-day volume-weighted average price.

Subject to shareholder approval, Creso will provide one option to shareholders for every four shares issued.

These options will be exercisable at 38 cents with expiry 12 months from issue.

EverBlu Capital will act as lead manager and, subject to shareholder approval, receive a 6 per cent fee and one million broker shares for every $5 million raised.

Creso will use the money to undertake psychedelic clinical trials, increase cannabis product marketing in Canada and fund the acquisition of Halucenex Life Sciences.

“Key short-term focus will include finalising the acquisition of Halucenex and undertaking clinical trials. Importantly, the acquisition provides the company with access to another lucrative vertical and potential revenue stream,” Non-Executive Chairman Adam Blumenthal said.

“We will also be ramping up our nutraceutical division and preparing for the anticipated legalisation of cannabis in the U.S. through our Canadian operations,” he added.

Creso is down 6.52 per cent on the market and shares are trading at 21.5 cents at 11:31 am AEDT.

CPH by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug